Multimeric Fusion Polypeptides for Receptor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for activating target receptors, such as those in the Eph and Tie families, are limited in their ability to effectively multimerize and activate these receptors, which is crucial for various therapeutic and diagnostic applications.
Innovation Solution
Development of multimeric fusion polypeptides that include specific polypeptides for target receptors, multimerizing components, and spacer sequences to enhance receptor activation, allowing for the formation of activating dimers that can bind to and cluster multiple receptors, thereby activating them more effectively than traditional antibodies or natural ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antibodies or natural ligands are used to activate target receptors, then the method is simple and well-established, but the capacity to activate and cluster multiple receptors is limited
Solution Approach 1:
The patent merges multiple functional domains into a single fusion polypeptide molecule. Specifically, it combines a multimerizing component (such as Fc domains of IgG) with one or more polypeptides specific for the target receptor (A and A′). This merging creates a unified structure that can simultaneously multimerize and bind to multiple receptors, thereby enhancing activation capacity while maintaining a manageable structural complexity through modular design.
Solution Approach 2:
The fusion polypeptide represents a composite molecular structure combining different functional elements: the multimerizing component (M) that enables self-assembly into multimers, and the receptor-specific polypeptides (A and A′) that provide target binding specificity. This composite approach allows the molecule to exhibit both multimerization capability and receptor-specific binding in a single integrated structure, resolving the contradiction between activation capacity and structural complexity.
2Reliability
If multimeric fusion polypeptides are designed to cluster multiple receptors, then receptor activation capacity is improved, but the manufacturing and structural complexity increases
Solution Approach 1:
The fusion polypeptide is segmented into distinct functional modules: the multimerizing component (M) and the receptor-specific polypeptides (A and A′). This segmentation allows each module to be independently optimized and characterized. The multimerizing component can be designed to form predictable multimer structures (dimers, tetramers, etc.), while the receptor-specific portions maintain their binding functionality. This modular segmentation simplifies the manufacturing process by allowing standardized production of each domain and their controlled assembly.
Solution Approach 2:
The multimerizing component (M) serves multiple functions: it enables self-assembly into multimers, provides structural stability to the fusion polypeptide, and facilitates receptor clustering. By designing M with universal multimerization capability (such as using Fc domains that naturally dimerize), the patent creates a platform that can be applied to different target receptors by simply changing the A and A′ portions, thereby easing manufacturing through reusable core structures.
3Reliability
If the fusion polypeptide forms activating dimers that bind to multiple receptors, then therapeutic potential is enhanced, but the molecular complexity and difficulty of detection increase
Solution Approach 1:
The patent employs parameter changes in the design of the fusion polypeptide to optimize detection and characterization. By controlling the stoichiometry of components (X and Y values representing the number of A and A′ polypeptides), the multimerization state (through choice of M component), and the structural configuration, the patent creates molecules with defined physical and chemical parameters that facilitate detection. For example, the Fc domain-based multimerizing component provides characteristic properties (such as antibody Fc region epitopes) that can be detected using standard antibody-based assays, thereby reducing detection difficulty despite the enhanced therapeutic efficacy.
Data Source
AI summary
A fusion polypeptide comprising (A)x-M-(A′)y, wherein A and A′ are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A′ may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different ScFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.